About Pseudokinase FAM20A
Pseudokinase FAM20A (FAM20A) is a protein
from Homo sapiens identified by UniProt accession
Q96MK3, 541 residues long.
MolForge cross-references it against 0 known binders and
294 disease associations.
Target properties
| Protein name | Pseudokinase FAM20A |
| UniProt accession | Q96MK3 |
| Gene | FAM20A |
| Organism | Homo sapiens |
| Length | 541 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (294)
Diseases linked to this target (Open Targets).
- amelogenesis imperfecta type 1G · score 0.80
- heel bone mineral density · score 0.36
- blood phosphate measurement · score 0.31
- otosclerosis · score 0.31
- body height · score 0.30
- sitting height measurement · score 0.26
- phosphorus measurement · score 0.25
- genetic disorder · score 0.19
- platelet count · score 0.12
- Hypomaturation amelogenesis imperfecta · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96MK3-F1 | alphafold | PREDICTED | 85.24 | — |
Amino-acid sequence (541 residues)
MPGLRRDRLL TLLLLGALLS ADLYFHLWPQ VQRQLRPRER PRGCPCTGRA SSLARDSAAA ASDPGTIVHN FSRTEPRTEP AGGSHSGSSS KLQALFAHPL YNVPEEPPLL GAEDSLLASQ EALRYYRRKV ARWNRRHKMY REQMNLTSLD PPLQLRLEAS WVQFHLGINR HGLYSRSSPV VSKLLQDMRH FPTISADYSQ DEKALLGACD CTQIVKPSGV HLKLVLRFSD FGKAMFKPMR QQRDEETPVD FFYFIDFQRH NAEIAAFHLD RILDFRRVPP TVGRIVNVTK EILEVTKNEI LQSVFFVSPA SNVCFFAKCP YMCKTEYAVC GNPHLLEGSL SAFLPSLNLA PRLSVPNPWI RSYTLAGKEE WEVNPLYCDT VKQIYPYNNS QRLLNVIDMA IFDFLIGNMD RHHYEMFTKF GDDGFLIHLD NARGFGRHSH DEISILSPLS QCCMIKKKTL LHLQLLAQAD YRLSDVMRES LLEDQLSPVL TEPHLLALDR RLQTILRTVE GCIVAHGQQS VIVDGPVEQL APDSGQANLT S
Explore Pseudokinase FAM20A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets